Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone

Therapies that target cancer cells may have unexpected effects on the tumor microenvironment that affects therapy outcomes or render therapy resistance. Prostate cancer (PCa) bone metastasis is uniquely associated with osteoblastic bone lesions and treatment with cabozantinib, a VEGFR-2 and MET inhi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Yu, Kai-Jie, Li, Jeffrey K., Lee, Yu-Chen, Yu, Guoyu, Lin, Song-Chang, Pan, Tianhong, Satcher, Robert L., Titus, Mark A., Yu-Lee, Li-Yuan, Weng, Wen Hui, Gallick, Gary E., Lin, Sue-Hwa
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650395/
https://ncbi.nlm.nih.gov/pubmed/29088840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20489
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky